Tyrosine Kinase Inhibitors

Understanding Targeted Therapies for HER2-Positive Advanced Breast Cancer: Focus on Five Categories

by

The human epidermal growth factor receptor 2 (HER2) is a known important molecular target in breast cancer. As one of the proto-oncogenes, HER2 is often associated with aggressiveness, recurrence, metastasis, and poor prognosis. The clinical application of the anti-HER2 drug trastuzumab has significantly improved the diagnosis and treatment patterns and prognosis of HER2-positive breast cancer, … Read more

Chapter 1: Chronic Myeloid Leukemia

by
Chapter 1: Chronic Myeloid Leukemia

Definition:Chronic Myeloid Leukemia (CML) is caused by the chromosomal translocation (9;22)(q34.1;q11.2), which leads to the formation of the Philadelphia (Ph) chromosome containing the BCR::ABL1 fusion gene. The BCR::ABL1 oncogenic protein acts as a constitutively activated tyrosine kinase, driving malignant transformation by activating multiple signaling pathways. Granulocytes are the main proliferative component, but all myeloid lineages … Read more